Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service agreement to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.   Under the agreement, BITT will leverage Selexis’ SUREtechnology Platform, a suite of proprietary modular technologies designed to overcome the challenges of protein-expression and deliver the high-performance research cell banks...